569682-60-6

Basic information

• Product Name: CarbaMic acid, N-(2,2-diMethoxyethyl)-N-2-propen-1-yl-, phenylMethyl ester
• Synonyms: CarbaMic acid, N-(2,2-diMethoxyethyl)-N-2-propen-1-yl-, phenylMethyl ester;benzyl N-(2,2-dimethoxyethyl)-N-prop-2-enylcarbamate;Benzyl Allyl(2,2-Dimethoxyethyl)Carbamate
• CAS NO: 569682-60-6
• Molecular Formula: C₁₅H₂₁NO₄
• Molecular Weight: 279.33154
• Mol File: 569682-60-6.mol

Chemical Properties

• Boiling Point: 373.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.088±0.06 g/cm3(Predicted)
• PKA: -1.50±0.70(Predicted)
• CAS DataBase Reference: CarbaMic acid, N-(2,2-diMethoxyethyl)-N-2-propen-1-yl-, phenylMethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, N-(2,2-diMethoxyethyl)-N-2-propen-1-yl-, phenylMethyl ester(569682-60-6)
• EPA Substance Registry System: CarbaMic acid, N-(2,2-diMethoxyethyl)-N-2-propen-1-yl-, phenylMethyl ester(569682-60-6)

Safety Data

• Hazardous Substances Data: 569682-60-6(Hazardous Substances Data)

Usage

Uses

Used in Agricultural Industry:
CarbaMic acid, N-(2,2-diMethoxyethyl)-N-2-propen-1-yl-, phenylMethyl ester is used as a pesticide and insecticide for controlling pests and insects that threaten crop yields. Its application helps protect crops from damage, ensuring a stable food supply.
Used in Pharmaceutical Industry:
Although still under investigation, CarbaMic acid, N-(2,2-diMethoxyethyl)-N-2-propen-1-yl-, phenylMethyl ester has been studied for its potential use in pharmaceuticals and medicinal applications. Its specific role in this industry is yet to be fully determined, but the compound's unique properties make it a promising candidate for future research and development.

Upstream product

• 114790-39-5 benzyl N-(2,2-dimethoxyethyl)carbamate 
• 106-95-6 allyl bromide 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 569682-62-8 N-(2,2-dimethoxyethyl)-N-(2-oxoethyl) carbamic acid benzyl ester 
• 370880-75-4 benzyl N-(2-oxoethyl)-N-(prop-2-en-1-yl)carbamate 
• 569682-63-9 (-)-N-[2-(1,3-dioxo-1λ⁴,3λ⁴-dithian-2-ylidene)ethyl]-N-(2,2-dimethoxyethyl)carbamic acid benzyl ester 
• 569682-65-1 (+)-cis-(4S,3R)-4-benzylaminopyrrolidine-1,3-dicarboxylic acid-1-benzyl ester 
• 569682-64-0 (+)-[1'R,3'R]-1-benzyl-1',3'-dioxospiro[1',3'-dithiane-2',3-pyrrolo[3,4-c]isoxazole]-5-carboxylic acid benzyl ester 
• 370880-76-5 benzyl N-[2-(hydroxyimino)ethyl]-N-(prop-2-en-1-yl)carbamate 
• 1017789-40-0 3-amino-4-hydroxymethyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 1255099-67-2 3-tert-butoxycarbonylamino-4-hydroxymethyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 1293940-34-7 3-tert-butoxycarbonylamino-4-methanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid benzyl ester 
• 370880-79-8 3-benzyl 6-(tert-butyl)-3,6-diazabicyclo[3.2.0]heptane-3,6-dicarboxylate 
• 370880-87-8 benzyl 3,6-diazabicyclo[3.2.0]heptane-3-carboxylate 
• 122848-57-1 tert-butyl-3,6-diazabicyclo[3,2,0]heptane-6-carboxylate 
• 1333161-18-4 C₁₇H₂₄N₂O₃S 
• 1333161-21-9 C₂₅H₄₀N₂O₅SSi 

Relevant articles and documents

CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

A TETRAHYDROPYRROLO[3,4-D][1,3]THIAZINE-DERIVATIVE AS BACE INHIBITOR

The present invention provides a compound of Formula I: which is crystalline. The compound of Formula (I) is useful in the treatment of Akzheimer's disease (BACE imnhibitor).

TOSYLATE SALT OF N-[3-[(4AR,7AS)-2-AMINO-6-(5-FLUOROPYRIMIDIN-2-YL)-4,4A,5,7-TETRAHYDROPYRROLO[3,4-D][1,3]THIAZIN-7A-YL]-4-FLUORO-PHENYL]-5-METHOXY-PYRAZINE-2-CARBOXAMIDE

The present invention provides a tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5- fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro- phenyl]-5-methoxy-pyrazine-2-carboxamide.

As the NS4B inhibitor benzofuran analogs (by machine translation)

The present invention discloses a kind of as NS4B benzofuran analogue inhibitors, in particular to the formula (I) below or a pharmaceutically acceptable salt thereof. (by machine translation)

TETRAHYDROPYRROLOTHIAZINE COMPOUNDS

The present invention provides a compound of Formula (I): wherein R is H or F; and A is:(A), (B), (C) or (D); or a pharmaceutically acceptable salt thereof.

TETRAHYDROPYRROLOTHIAZINE COMPOUNDS

The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R1 is H or F; R2 is H, —CH2OH, C1-C3 alkyl, R3 is H, F, or CN; R4 is H, F; or CN; and R5 is H, —CH3, or —OCH3; or a pharmaceutically acceptable salt thereof.

FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS

Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS

Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel α4β2 nicotinic acetylcholine receptor selective agonists

A series of novel, potent neuronal nicotinic acetylcholine receptor (nAChR) ligands derived from 3,6-diazabicyclo[3.2.0]heptane have been synthesized and evaluated for binding affinity and agonist activity at the α4β2 nAChR subtype. Structure-activity relationship studies of these novel nAChR ligands focused on substitution effects on the pyridine ring, as well as stereo- and regiochemical influences of the 3,6-diazabicyclo[3.2.0]heptane core. Small 5-substituents on the pyridine ring had a modest impact on the binding affinities and functional activities. 6-Bromo, 6-chloro, and 6-methyl substituents on the pyridine ring led to increased binding affinities and improved functional activities. Most of the 6-N-pyridinyl-substituted 3,6-diazabicyclo[3.2.0]heptanes are selective for the α4β2 nAChR subtype. Compounds (1R,5S)-25, (1R,5S)-55, and (1R,5S)-56 were virtually inactive as agonists at the hα3β4 nAChR but retained potency and efficacy at the hα4β2 nAChR subtype. 3-N-Pyridinyl-substituted series demonstrated more complex SAR. (1R,5R)-39, (1R,5R)-41, and (1R,5R)-42 were found to be much more potent at the hα3β4 nAChR subtype, whereas (1R,5R)-38 and (1R,5R)-40 were very selective at the hα4β2 nAChR subtype. The SAR studies of these novel ligands led to the discovery of several compounds with interesting in vitro pharmacological profiles.

(1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate

The present invention relates to the salt (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate and to methods of preparing the salt.